Craig Pigott

Craig brings both biochemistry and protein engineering expertise to Innovative Targeting Solutions. He was part of the founding team in 2008 and has been instrumental in the creation of the HuTARG technology and its applications and is an inventor on the company’s core patents. His career has focused on the development of novel technologies for drug development, at ImmGenics Pharmaceuticals isolating antibodies directly from in vivo sources and at Abgenix exploiting a transgenic system, XenoMouse. Craig completed his Ph.D. at the University of Cambridge, Department of Biochemistry, where he focused on protein engineering and phage display in collaboration with Cambridge Antibody Technology. He completed his postdoctoral research at the University of British Columbia, Department of Biochemistry where he studied cell signaling. Craig is responsible for the continued advancement of the technology and its application to the company’s internal pipeline.